Requip (ropinirole) is a non-ergoline dopamine agonist specifically formulated to manage the motor symptoms of Parkinson’s disease and moderate-to-severe primary Restless Legs Syndrome (RLS). By selectively activating dopamine receptors in the brain, it helps restore neurotransmitter balance, improving motor control, reducing involuntary movements, and alleviating the uncomfortable sensations and urge to move associated with RLS. Clinically proven and widely prescribed, Requip offers a targeted therapeutic approach to enhance daily functioning and quality of life for patients navigating these chronic neurological conditions.

Features

• Active ingredient: ropinirole hydrochloride
• Available in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg strengths
• Non-ergoline dopamine D2-receptor agonist
• Selective activation of dopamine receptors in the striatum
• Rapid absorption with peak plasma concentration within 1–2 hours
• Extensive liver metabolism via CYP1A2 enzyme
• Elimination half-life of approximately 6 hours
• Bioavailability of 55%, unaffected by food

Benefits

• Reduces tremor, rigidity, and bradykinesia in Parkinson’s disease
• Diminishes unpleasant sensations and involuntary leg movements in RLS
• Improves sleep quality and daytime alertness for RLS patients
• Enhances overall motor function and mobility
• Delays the need for levodopa therapy in early Parkinson’s
• May allow for lower levodopa doses in advanced Parkinson’s, reducing dyskinesia risk

Common use

Requip is indicated for the treatment of Parkinson’s disease, both as monotherapy in early stages and as adjunctive therapy to levodopa in later stages. It is also approved for the management of moderate-to-severe primary Restless Legs Syndrome. Patients with Parkinson’s experience improved motor control, while those with RLS report reduced sensory symptoms and better sleep continuity.

Dosage and direction

For Parkinson’s disease, begin with 0.25 mg three times daily. Titrate gradually: increase by 0.25 mg per dose each week for four weeks, then by 0.5 mg per dose weekly to achieve optimal response. Maintenance dose typically ranges from 3–9 mg daily, divided into three doses; maximum 24 mg/day.
For Restless Legs Syndrome, start with 0.25 mg once daily, 1–3 hours before bedtime. Increase to 0.5 mg after two days, then to 1 mg at the end of the first week, and thereafter as needed up to 4 mg daily. Take with food to minimize nausea.

Precautions

Monitor for emerging dizziness, orthostatic hypotension, or syncope, especially during dose escalation. Hallucinations or compulsive behaviors (e.g., gambling, shopping) may occur; evaluate patients for risk factors. Use caution in patients with hepatic impairment due to metabolism via CYP1A2. advise against abrupt discontinuation to avoid withdrawal symptoms or neuroleptic malignant syndrome-like events. Pregnancy Category C: use only if potential benefit justifies potential risk.

Contraindications

Hypersensitivity to ropinirole or any component of the formulation. Concurrent use with antipsychotics or other dopamine antagonists is not recommended. Severe hepatic impairment. History of significant cardiac arrhythmias or serious cardiovascular disease without careful monitoring.

Possible side effect

Common: nausea, dizziness, somnolence, vomiting, fatigue.
Less common: orthostatic hypotension, syncope, hallucinations, impulse control disorders, peripheral edema.
Rare: pulmonary fibrosis, pleural effusion, retroperitoneal fibrosis; priapism (seek immediate medical attention).

Drug interaction

CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) may increase ropinirole plasma levels—dose adjustment may be needed. Dopamine antagonists (e.g., phenothiazines, butyrophenones, metoclopramide) may diminish efficacy. Estrogens may reduce clearance of ropinirole. Alcohol and other CNS depressants may enhance sedative effects.

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose. For once-daily RLS dosing, if missed, skip and resume the next day at the regular time.

Overdose

Symptoms may include agitation, hypotension, nausea, vomiting. General supportive measures are recommended; monitor ECG and vital signs. Dopamine antagonists may be used, but may worsen Parkinsonian symptoms. Dialysis is unlikely to be beneficial due to high protein binding.

Storage

Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). Keep in original container, tightly closed, and protect from light and moisture. Keep out of reach of children and pets.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment decisions, and personalized dosing. Do not start, stop, or change dosage without medical supervision.

Reviews

“After starting Requip for my Parkinson’s, I’ve noticed a significant improvement in my mobility and a reduction in tremors. The titration was gradual, and my neurologist monitored me closely for side effects.” – James, 68
“Requip has been life-changing for my restless legs. I finally sleep through the night. The first week was rough with nausea, but taking it with food helped immensely.” – Linda, 52
“As a caregiver, I’ve seen Requip help my father regain independence. We did notice some dizziness initially, but adjusting the dose made a difference.” – Maria, 44
“Effective for RLS, though I experienced mild drowsiness during the day. My doctor adjusted the timing, and it’s much better now.” – Robert, 61